FIM
CRSP icon

FWL Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

FWL Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$3.4K – 329
2025
Q1 		$3.4K Hold
100
– – ﹤0.01% 263
2024
Q4 		$3.94K Hold
100
– – ﹤0.01% 276
2024
Q3 		$4.7K Buy
+100
New +$5.07K ﹤0.01% 261

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FWL Investment Management's CRSP Position: Q2 2025 in Review

FWL Investment Management sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 100 shares — an estimated $3.4K sold.

FWL Investment Management first reported a position in CRSP in Q3 2024 and held it in 3 quarters. The position peaked at $4.7K in Q3 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • FWL Investment Management reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • FWL Investment Management sold 100 CRISPR Therapeutics shares in Q2 2025, an estimated $3.4K.
  • FWL Investment Management first reported a position in CRISPR Therapeutics in Q3 2024 and held it in 3 quarters.
  • FWL Investment Management's CRISPR Therapeutics position peaked at $4.7K in Q3 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on FWL Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.